|This Slide: #19 of 100|
Slide #19. Bristol-Myers Squibb — iPierian, Inc.
Bristol-Myers Squibb (NYSE:BMY)
Bristol-Myers Squibb Company (NYSE:BMY) and iPierian, Inc. announced today that Bristol-Myers Squibb has acquired iPierian, a privately held biotechnology company focused on the discovery and development of new treatments for Tauopathies, a class of neurodegenerative diseases associated with the pathological aggregation of Tau protein in the human brain.
Bristol-Myers Squibb is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. Co.'s primary products include: Revlimid®, in which Revlimid (lenalidomide) is an oral immunomodulatory drug that in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma; and Eliquis®, in which Eliquis (apixaban) is an oral Factor Xa inhibitor indicated for the reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE and reduction in risk of recurrence following initial therapy.
Bristol-Myers Squibb SEC Filing Email Alerts Service
Open the BMY Page at The Online Investor »
Free BMY Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts
Buy (2.85 out of 4)